Amyotrophic Lateral Sclerosis Treatment Market by Treatments (Medication, Stem Cell Transplant, and Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global amyotrophic lateral sclerosis treatment market size is projected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing awareness about ALS, growing geriatric population, and rising incidence rate.
 

Amyotrophic lateral sclerosis (ALS) disease is also known as Lou Gehrig's disease. It is a progressive neurodegenerative disorder that damages nerve cells present in the central nervous system and responsible for controlling the voluntary muscles. There are some common symptoms such as weakness as a result of a reduction in the arms or legs muscles size, muscle twitching, and stiff muscles. Around 50% of the total people suffering from amyotrophic lateral sclerosis might lose the capability to speak, swallow, walk, breath, and use their hands.

As stated by the National Institute of Neurological Disorders and Stroke (NINDS), ALS patients often die after within 3-5 years of failure of respiratory. Sporadic and familial are two types of ALS disease. The sporadic is most common type and holds around 90% of all cases in the U.S. Familial type of ALS is hereditary, in which there is about 50% of chance genetic mutation inheritance and gradually disorder is developed. In 30-40% of familial ALS patients the defect is usually found in the C9ORF72 gene. Frontotemporal dementia (FTD) condition is generated due to mutation in C9ORF72 gene, this condition is developed with ALS as comorbidity referred to as ALS-FTD.
There is no permanent cure for ALS disease. But there are some treatments such as stem cell therapies and medications for slows down the disease progression, management of the symptoms, and prevention of unnecessary complications. Changing lifestyle results in increasing risk of developing the disorder, which makes a demand of targeted treatment options and novel therapeutics approaches.

Market Trends, Drivers, Restraints, and Opportunities

• Growing number of patients affected by ALS is a key factor driving the market growth over the forecast period.
• Rising government initiatives for R&D of rare disease and favorable approvals from Food and Drug Administration (FDA) generates various opportunities for companies are expected to fuel the growth of the market.
• Increase in launch of novel medicines, growth expenditure on healthcare, and well developed healthcare infrastructure are anticipated to propel the market growth.
• Increase in strategic collaborations of research institutes and key companies for ALS treatment development, sedentary lifestyle, and rising risk of developing ALS are estimated to fuel the growth of the market.
• High cost of treatment and lack of awareness about disease among people are major factors that can hamper the growth of ALS treatment market in the coming years.
• Low availability of treatment and lower prevalence rate are expected to impede the market growth over the forecast period.

Scope of the Report

The report on the global amyotrophic lateral sclerosis treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Stem cell transplant segment is expected to expand at a rapid pace
In terms of treatments, the amyotrophic lateral sclerosis treatment market is segmented into medication, stem cell transplant, and others. The medication segment is expected to represent a key share of the market in the coming years. Only two drugs are approved for ALS treatment, Rilutek (riluzole), and Radicava (edaravone). The Nuedexta (dextromethorphan/quinidine) drug is approved by FDA for pseudobulbar affect treatment, comorbidity of ALS.

On the other hand, the stem cell transplant segment is anticipated to expand at a rapid pace during the forecast period owing to growing demand of advanced treatment and new approach. Various initiatives are taken by government authoritative bodies and the Collaborative ALS Drug Discovery Initiative (CADDI) for rapid development of novel drugs and treatments which is projected to increase in the number of clinical trials and introduction of pipeline drugs in coming years.
 

Hospital pharmacies segment is projected to hold a key market share
Based on distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment is expected to hold a key share of the market during the forecast period. The need of multiple times visits and stays during ALS treatment is driving the segment growth. Large number of patients prefers hospital pharmacies and retail pharmacies. This is attributed to quick and easy access to various drugs and adequate products offered by these distribution channels.

Other distribution channels in ALS treatment market such as clinics, diagnostics laboratories, and online pharmacies. Online pharmacies are also growing owing to increasing popularity of e-commerce channels which offers multiple options including in-depth information about drugs.

Asia Pacific is expected to dominate the market
On the basis of regions, the amyotrophic lateral sclerosis treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to huge demand of ALS drugs, high healthcare expenditure, established healthcare infrastructure, and favorable reimbursement policies. As per published data in Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, in 2015 around 16,500 ALS were found in the U.S.

On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years. In this region, industry is witnessing a rising generation of revenue from riluzole generic manufacturers, majorly in emerging countries such as India and China. Increasing investment in R&D, promising initiatives by government and manufacturers, and plenty of unexplored opportunities are some major factors fuelling the market growth.
 

Segments

Segments Covered in the Report
The global amyotrophic lateral sclerosis treatment market has been segmented on the basis of

Treatments

• Medication
• Stem Cell Transplant
• Others

Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Others

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Mitsubishi Tanabe Pharma Corporation
• Otsuka Pharmaceutical Co., Ltd.
• BrainStorm Therapeutics
• Biogen Inc.
• Corestem
• AB Science
• F.Hoffmann-La Roche AG
• Biohaven Pharmaceutical
• Sun Pharmaceutical
• Ionis Pharmaceuticals, Inc.

Competitive Landscape

Key players competing in the amyotrophic lateral sclerosis treatment market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F.Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc.

Many major market players are implementing several business strategies including mergers, acquisitions, partnerships, collaborations, expansion into emerging counties, and product launches to enhance their market shares.